Item 2.02 Results of Operations and Financial Condition. On May 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three months ended March, 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K. The Company’s press release contains non-GAAP financial measures.…
Filed May 14, 2026Accepted May 14, 2026, 8:00 AM EDTCIK 1858685Accession 0001493152-26-022875
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item
2.02 Results of Operations and Financial Condition.
On
May 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for
the three months ended March, 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current
Report on Form 8-K.
The
Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of
a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded
or included in the most directly comparable measure calculated and presented in accordance with United States generally accepted accounting
principles, or GAAP. Pursuant to the requirements of Regulation G, the Company has provided within the press release quantitative reconciliations
of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
The
information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference
in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm
EX-99.1
2
ex99-1.htm
EX-99.1
Exhibit 99.1
Biofrontera
Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Woburn,
MA (May 14, 2026) (GLOBE NEWSWIRE) - Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing
in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three
months ended March 31, 2026 and provided a business update.
First
Quarter Financial Highlights
Gross
margins were about 80%, an 18 percentage points increase compared to approximately 62% in
Q1 2025, reflecting the first full quarter under the new earnout structure following the
closing of the strategic transaction with Biofrontera AG in October 2025 (the “Strategic
Transaction”).
───────────────────────────────────────────────────────────────────────────────────────────────────────
Revenues
for Q1 2026 were $10.1 million, a ~17% increase compared to $8.6 million for the same period
in 2025.
Operating
loss was $4.3 million in Q1 2026 compared to a loss of $4.5 million in Q1 2025.
Adjusted
EBITDA improved to $(3.6) million from $(4.4) million in Q1 2025,…